Clinical Trials on MRSA Enteritis in Australia

Total 20 results

Bristol-Myers Squibb

Terminated

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Crohn's Disease | Granulomatous Colitis | Crohn's Enteritis | Granulomatous Enteritis

Canada, Germany, Taiwan, United States, Spain, Australia, Poland, Russian Federation, Japan, Korea, Republic of, Romania, Italy, United Kingdom, Belgium, Brazil, China, Czechia, France, Hungary, Ireland, Israel, Mexico, Netherlands, P... and more
Novartis Pharmaceuticals

Recruiting

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) (REPLENISH-EXT)

Polymyalgia Rheumatica

Australia
Shire

Completed

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs (TOSCA)

Crohn's Disease | Ulcerative Colitis | Ileitis | Granulomatous Colitis | Ileo-colonic and Colonic Crohn's Disease | Regional Enteritis

France, Belgium, Austria, Germany, Netherlands
Royal North Shore Hospital

Completed

Giant Cell Arteritis and PET Scan (GAPS) Study

Giant Cell Arteritis

Australia
Syneos Health
Dr. Reddy's Laboratories Limited

Completed

Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers

Rheumatoid Arthritis | Giant Cell Arteritis

New Zealand, Australia, India
Medical University of Vienna

Completed

A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)

Polymyalgia Rheumatica

Austria
AbbVie

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

Giant Cell Arteritis (GCA)

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Romania, Russian Federation, Spain, Sweden, Switzerland, United...
GlaxoSmithKline

Terminated

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

Giant Cell Arteritis

United States, Spain, Germany, Italy, Belgium, France, Netherlands, Australia, United Kingdom, Hungary, Poland, Bulgaria, New Zealand
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Giant Cell Arteritis (GCA)

United States, Spain, Turkey, France, Hungary, Australia, Belgium, Germany, Israel, Argentina, Chile, Greece, Portugal, Bulgaria, Italy, Switzerland, Brazil, Czechia, Denmark, Estonia, Austria, Guatemala, United Kingdom, Finland, Russian... and more
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Giant Cell Arteritis

Poland, United States, Spain, France, Austria, Belgium, Italy, Romania, Switzerland, Germany, Greece, Netherlands, Australia, Denmark, United Kingdom, Ireland, Bulgaria, Canada, Estonia, Serbia, Sweden
AbbVie

Terminated

A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 (AIM-PMR)

Polymyalgia Rheumatica

United States, Australia, Austria, Canada, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, United Kingdom
Kiniksa Pharmaceuticals, Ltd.

Completed

KPL-301 for Subjects With Giant Cell Arteritis

Giant Cell Arteritis

United States, Belgium, Croatia, Germany, Italy, Poland, Serbia, United Kingdom, Australia, Estonia, Ireland, Netherlands, New Zealand, Slovenia, Spain
University of Oxford
American College of Rheumatology; The European League Against Rheumatism (EULAR) and other collaborators

Unknown

American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS)

Giant Cell Arteritis | Wegener's Granulomatosis | Microscopic Polyangiitis | Polyarteritis Nodosa | Takayasu Arteritis | Churg Strauss Syndrome

Korea, Republic of, United States, Germany, Australia, Japan, Ireland, Belgium, Italy, Denmark, Slovenia, Switzerland, Canada, Argentina, Austria, China, Czech Republic, Egypt, Finland, France, Hungary, India, Mexico, Netherlands, New... and more
Sanofi
Regeneron Pharmaceuticals

Terminated

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Giant Cell Arteritis

Argentina, Estonia, France, United States, Australia, Belgium, Canada, Croatia, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Recruiting

A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis (ENGAGE)

Eosinophilic Gastritis | Eosinophilic Duodenitis | Eosinophilic Gastrointestinal Disease

United States, Poland, Italy, Japan, Australia
Sanofi
Regeneron Pharmaceuticals

Terminated

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Polymyalgia Rheumatica

Argentina, Estonia, France, Japan, United States, Australia, Belgium, Canada, Germany, Hungary, Israel, Italy, Netherlands, Russian Federation, Switzerland, United Kingdom, Spain
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH)

Polymyalgia Rheumatica

United States, Australia, Germany, Belgium, France, Spain, Italy, Lebanon, Switzerland, Japan, Israel, Argentina, Netherlands, Colombia, Chile, Hungary, Poland, Turkey, Czechia, Brazil, South Africa, Mexico, Canada, Denmark, United Kingdom
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
Theravance Biopharma

Terminated

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (REDWOOD)

Parkinson's Disease (PD) | MSA | Symptomatic Neurogenic Orthostatic Hypotension | Pure Autonomic Failure (PAF)

United States, Spain, United Kingdom, Canada, France, Estonia, Australia, Israel, Denmark, Italy, Poland, New Zealand, Germany, Ukraine, Austria, Bulgaria, Portugal, Hungary, Russian Federation
Theravance Biopharma

Recruiting

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy (CYPRESS)

MSA - Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, United Kingdom, Hungary, Italy, Argentina, Austria, Poland, Germany, Portugal, Belgium, Brazil, Denmark, Canada, France, Chile, Estonia

Clinical Trials on MRSA Enteritis in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations